English | 繁體

Search in the results

UM

Browse/Search Results:  1-3 of 3 Help

Selected(0)Clear Items/Page:    Sort:
iRGD-modified lipid–polymer hybrid nanoparticles loaded with isoliquiritigenin to enhance anti-breast cancer effect and tumor-targeting ability Journal article
Gao F., Zhang J., Fu C., Xie X., Peng F., You J., Tang H., Wang Z., Li P., Chen J.. iRGD-modified lipid–polymer hybrid nanoparticles loaded with isoliquiritigenin to enhance anti-breast cancer effect and tumor-targeting ability[J]. International Journal of Nanomedicine, 2017, 12, 4147-4162.
Authors:  Gao F.;  Zhang J.;  Fu C.;  Xie X.;  Peng F.; et al.
Favorite | TC[WOS]:79 TC[Scopus]:91 | Submit date：2018/12/28
Breast Cancer  Irgd  Isoliquiritigenin  Lipid–polymer Hybrid Nps  
iRGD-modified lipid-polymer hybrid nanoparticles loaded with isoliquiritigenin to enhance anti-breast cancer effect and tumor-targeting ability Journal article
Gao, Fei, Zhang, Jinming, Fu, Chaomei, Xie, Xiaoming, Peng, Fu, You, Jieshu, Tang, Hailin, Wang, Zhiyu, Li, Peng, Chen, Jianping. iRGD-modified lipid-polymer hybrid nanoparticles loaded with isoliquiritigenin to enhance anti-breast cancer effect and tumor-targeting ability[J]. INTERNATIONAL JOURNAL OF NANOMEDICINE, 2017, 12, 4147-4162.
Authors:  Gao, Fei;  Zhang, Jinming;  Fu, Chaomei;  Xie, Xiaoming;  Peng, Fu; et al.
Favorite | TC[WOS]:79 TC[Scopus]:91  IF:6.6/7.5 | Submit date：2018/10/30
Isoliquiritigenin  Irgd  Lipid-polymer Hybrid Nps  Breast Cancer  
iRGD decorated lipid-polymer hybrid nanoparticles for targeted co-delivery of doxorubicin and sorafenib to enhance anti-hepatocellular carcinoma efficacy Journal article
Zhang J., Hu J., Chan H.F., Skibba M., Liang G., Chen M.. iRGD decorated lipid-polymer hybrid nanoparticles for targeted co-delivery of doxorubicin and sorafenib to enhance anti-hepatocellular carcinoma efficacy[J]. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12(5), 1303.
Authors:  Zhang J.;  Hu J.;  Chan H.F.;  Skibba M.;  Liang G.; et al.
Favorite | TC[WOS]:95 TC[Scopus]:105 | Submit date：2018/10/30
Active Targeting  Doxorubicin  Hepatocellular Carcinoma  Irgd Peptide  Sorafenib